CD44 and cancer: In fact, PP-HA-BSA-NPs effectively targeted these cancer cell lines expressing CD44 while retaining the high anticancer activity of the free drug, allowed a minimum loading of 10-fold the IC50 value, and showed an exceptional safety profile.